Changing MIC Breakpoints: Do Mechanisms Count

More documents

Recommendations

Info

New CLSI Guidelines 2010 • Problem with this approach Clinical studies show patients with “susceptible” <strong>MIC</strong>s + ESBL fail therapy 8
Clinical Studies • No randomized controlled trials have ever been performed that evaluated the use of various comparator antibiotics in treatment of serious infections due to ESBL-producing organisms • It is unlikely that such studies will ever be performed • Existing data comes only from retrospective studies 9
Page 1 and 2: Changing MIC Breakpoints: Do Mechan
Page 3 and 4: • The major issue is whether the
Page 5 and 6: CLSI Guidelines Staph spp. Table 2
Page 7: New CLSI Guidelines 2010 • This d
Page 11 and 12: New CLSI Guidelines 2010 • Proble
Page 13 and 14: MICs in g/ml: SHV-3 producing Citro
Page 15 and 16: Efficacy of different beta-lactams
Page 21 and 22: CAP Survey D-C 2007 D-19 C. freundi
Page 23 and 24: New CLSI Guidelines 2010 • Proble
Page 25 and 26: MIC Reproducibility • In this imp
Page 27 and 28: Enterobacteriaceae Revised Breakpoi
Page 29 and 30: Cephaloporin Breakpoints Following
Page 31: New CLSI Guidelines 2010 • Proble
Page 34 and 35: Why labs should continue to perform
Page 36 and 37: Are the New CLSI Breakpoints the Co
Page 38 and 39: Something to Think About • Breakp
Page 40 and 41: Something to Think About • Antibi
Page 42 and 43: Personalized Antibiotic Report •
Page 44 and 45: Personalized Antibiotic Report •
Page 46: Are the New CLSI Breakpoints the Co

Changing MIC Breakpoints: Do Mechanisms Count

Create successful ePaper yourself

Delete template?

Save as template?